Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5011) 5011
Book Review (1008) 1008
Publication (322) 322
Book Chapter (42) 42
Conference Proceeding (21) 21
Book / eBook (15) 15
Dissertation (12) 12
Newspaper Article (7) 7
Web Resource (5) 5
Trade Publication Article (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4020) 4020
humans (3305) 3305
oncology (1946) 1946
female (1929) 1929
platinum (1730) 1730
cancer (1712) 1712
chemotherapy (1646) 1646
cisplatin (1516) 1516
middle aged (1185) 1185
aged (1067) 1067
animals (1060) 1060
male (1030) 1030
antineoplastic agents - therapeutic use (1023) 1023
antineoplastic combined chemotherapy protocols - therapeutic use (994) 994
adult (927) 927
pharmacology & pharmacy (810) 810
ovarian neoplasms - drug therapy (745) 745
antineoplastic agents - pharmacology (694) 694
ovarian cancer (680) 680
treatment outcome (638) 638
care and treatment (588) 588
platinum compounds - therapeutic use (585) 585
cell line, tumor (563) 563
lung neoplasms - drug therapy (548) 548
analysis (539) 539
carboplatin (524) 524
cytotoxicity (492) 492
mice (485) 485
biochemistry & molecular biology (470) 470
antineoplastic agents - chemistry (466) 466
carcinoma (453) 453
toxicity (450) 450
platinum complexes (438) 438
carcinoma, non-small-cell lung - drug therapy (434) 434
apoptosis (431) 431
research (425) 425
dna (406) 406
chemistry, inorganic & nuclear (398) 398
drugs (398) 398
tumors (397) 397
organoplatinum compounds - therapeutic use (394) 394
prognosis (394) 394
drug resistance, neoplasm (393) 393
antineoplastic agents (386) 386
aged, 80 and over (376) 376
neoplasms - drug therapy (376) 376
in-vitro (375) 375
neoplasm staging (373) 373
paclitaxel (371) 371
survival (370) 370
platinum-based chemotherapy (366) 366
disease-free survival (360) 360
organoplatinum compounds - pharmacology (355) 355
oxaliplatin (341) 341
ovarian neoplasms - pathology (338) 338
cisplatin - administration & dosage (335) 335
cisplatin - therapeutic use (330) 330
platinum compounds (330) 330
cisplatin - pharmacology (329) 329
ligands (327) 327
antimitotic agents (326) 326
organoplatinum compounds - administration & dosage (317) 317
cancer therapies (311) 311
health aspects (311) 311
platinum compounds - administration & dosage (310) 310
antineoplastic agents - adverse effects (309) 309
antineoplastic combined chemotherapy protocols - adverse effects (304) 304
antineoplastic agents - administration & dosage (298) 298
medicine & public health (294) 294
retrospective studies (292) 292
nanoparticles (290) 290
chemistry, multidisciplinary (289) 289
hematology, oncology and palliative medicine (289) 289
therapy (288) 288
lung cancer (286) 286
antitumor-activity (282) 282
drug therapy (278) 278
chemistry, medicinal (272) 272
dose-response relationship, drug (272) 272
resistance (271) 271
drug resistance (269) 269
survival analysis (260) 260
organoplatinum compounds - chemistry (257) 257
survival rate (251) 251
article (250) 250
lung neoplasms - pathology (247) 247
deoxyribonucleic acid--dna (243) 243
platinum - chemistry (242) 242
cell lung-cancer (239) 239
proteins (239) 239
obstetrics & gynecology (235) 235
cell survival - drug effects (226) 226
apoptosis - drug effects (224) 224
phase-ii (223) 223
lung cancer, non-small cell (221) 221
rats (217) 217
chemistry (212) 212
gemcitabine (210) 210
phase-ii trial (209) 209
patients (207) 207
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5016) 5016
Japanese (17) 17
Russian (14) 14
Chinese (13) 13
French (13) 13
German (9) 9
Spanish (5) 5
Hungarian (4) 4
Polish (3) 3
Italian (2) 2
Bulgarian (1) 1
Czech (1) 1
Dutch (1) 1
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
by Reck, Martin and Rodríguez-Abreu, Delvys and Robinson, Andrew G and Hui, Rina and Csőszi, Tibor and Fülöp, Andrea and Gottfried, Maya and Peled, Nir and Tafreshi, Ali and Cuffe, Sinead and O’Brien, Mary and Rao, Suman and Hotta, Katsuyuki and Leiby, Melanie A and Lubiniecki, Gregory M and Shentu, Yue and Rangwala, Reshma and Brahmer, Julie R and KEYNOTE-024 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1823 - 1833
In a randomized trial involving patients with previously untreated advanced non–small-cell lung cancer, pembrolizumab was associated with a higher response... 
TRIAL | MEDICINE, GENERAL & INTERNAL | KEYNOTE-012 | MELANOMA | IPILIMUMAB | Antibodies, Monoclonal, Humanized - adverse effects | Lung Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Platinum Compounds - therapeutic use | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - adverse effects | Cell survival | PD-1 protein | Tumor cells | Lung cancer | Lymphoma | Cancer therapies | Patients | Pembrolizumab | Chemotherapy | Epidermal growth factor | Platinum | PD-L1 protein | Monoclonal antibodies | Comparative studies | Antitumor activity | Death | Protein-tyrosine kinase | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
by Bellmunt, Joaquim and de Wit, Ronald and Vaughn, David J and Fradet, Yves and Lee, Jae-Lyun and Fong, Lawrence and Vogelzang, Nicholas J and Climent, Miguel A and Petrylak, Daniel P and Choueiri, Toni K and Necchi, Andrea and Gerritsen, Winald and Gurney, Howard and Quinn, David I and Culine, Stéphane and Sternberg, Cora N and Mai, Yabing and Poehlein, Christian H and Perini, Rodolfo F and Bajorin, Dean F and KEYNOTE-045 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 11, pp. 1015 - 1026
In a randomized trial involving 542 patients with relapsed urothelial cancer, treatment with pembrolizumab resulted in overall survival of more than 10 months,... 
PHASE-III TRIAL | SUPPORTIVE CARE | MEDICINE, GENERAL & INTERNAL | VINFLUNINE PLUS | TRANSITIONAL-CELL CARCINOMA | NIVOLUMAB | FAILURE | CANCER | CHEMOTHERAPY | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vinblastine - therapeutic use | Paclitaxel - therapeutic use | Platinum Compounds - therapeutic use | Taxoids - therapeutic use | Urologic Neoplasms - pathology | Urologic Neoplasms - drug therapy | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Programmed Cell Death 1 Receptor - immunology | Urothelium | Adenocarcinoma | Care and treatment | Cancer patients | Health aspects | Urothelial cancer | Cell survival | PD-1 protein | Tumor cells | Metastasis | Patients | Pembrolizumab | Chemotherapy | Platinum | Medical prognosis | PD-L1 protein | Paclitaxel | Ligands | Death | Urothelial carcinoma | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
by Patel, Manish R and Ellerton, John and Infante, Jeffrey R and Agrawal, Manish and Gordon, Michael and Aljumaily, Raid and Britten, Carolyn D and Dirix, Luc and Lee, Keun-Wook and Taylor, Mathew and Schöffski, Patrick and Wang, Ding and Ravaud, Alain and Gelb, Arnold B and Xiong, Junyuan and Rosen, Galit and Gulley, James L and Apolo, Andrea B
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 51 - 64
The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or... 
TRACT | MULTICENTER | ANTI-PD-L1 ANTIBODY AVELUMAB | THERAPY | CISPLATIN | ONCOLOGY | TRANSITIONAL-CELL CARCINOMA | II TRIAL | SINGLE-ARM | CANCER | CHEMOTHERAPY | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Carcinoma - mortality | Antibodies, Monoclonal - therapeutic use | Male | Urothelium - pathology | Platinum Compounds - therapeutic use | Urologic Neoplasms - pathology | Urologic Neoplasms - drug therapy | Time Factors | Treatment Failure | Female | Carcinoma - secondary | Platinum Compounds - adverse effects | Carcinoma - drug therapy | Carcinoma - immunology | Urologic Neoplasms - mortality | Europe | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Agents, Immunological - therapeutic use | Asia | Urothelium - immunology | Aged | Urothelium - drug effects | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Carcinoma | Metastasis | Analysis | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
by Mirza, Mansoor R and Monk, Bradley J and Herrstedt, Jørn and Oza, Amit M and Mahner, Sven and Redondo, Andrés and Fabbro, Michel and Ledermann, Jonathan A and Lorusso, Domenica and Vergote, Ignace and Ben-Baruch, Noa E and Marth, Christian and Mądry, Radosław and Christensen, René D and Berek, Jonathan S and Dørum, Anne and Tinker, Anna V and du Bois, Andreas and González-Martín, Antonio and Follana, Philippe and Benigno, Benedict and Rosenberg, Per and Gilbert, Lucy and Rimel, Bobbie J and Buscema, Joseph and Balser, John P and Agarwal, Shefali and Matulonis, Ursula A and ENGOT-OV16 NOVA Investigators and ENGOT-OV16/NOVA Investigators and Region Östergötland and Medicinska fakulteten and Linköpings universitet and Institutionen för klinisk och experimentell medicin and Onkologiska kliniken US and Centrum för kirurgi, ortopedi och cancervård and Avdelningen för kliniska vetenskaper
The New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 22, pp. 2154 - 2164
Among patients with platinum-sensitive, recurrent ovarian cancer, the use of niraparib, a PARP inhibitor, was associated with a significantly longer duration... 
TRIAL | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | BRCA MUTATION CARRIERS | NEGATIVE BREAST-CANCER | Humans | Middle Aged | Homologous Recombination | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Bone Marrow - drug effects | Double-Blind Method | Kaplan-Meier Estimate | Disease-Free Survival | Piperidines - therapeutic use | Piperidines - adverse effects | Adolescent | Aged | Indazoles - adverse effects | Neoplasm Staging | Indazoles - therapeutic use | Care and treatment | Adenosine diphosphate | Research | Diagnosis | Patients | Health aspects | Ovarian cancer | Thrombocytopenia | Adenosine | Inhibitor drugs | Toxicity | Homologous recombination | Clinical trials | Poly(ADP-ribose) polymerase | Breast cancer | Cancer therapies | Survival | Ribose | Platinum | Bone marrow | Mutation | Drug therapy | Health risk assessment | Tumors | Neutropenia | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier
by Miura, Yutaka and Takenaka, Tomoya and Toh, Kazuko and Wu, Shourong and Nishihara, Hiroshi and Kano, Mitsunobu R and Ino, Yasushi and Nomoto, Takahiro and Matsumoto, Yu and Koyama, Hiroyuki and Cabral, Horacio and Nishiyama, Nobuhiro and Kataoka, Kazunori
ACS Nano, ISSN 1936-0851, 10/2013, Volume 7, Issue 10, pp. 8583 - 8592
Ligand-mediated drug delivery systems have enormous potential for improving the efficacy of cancer treatment. In particular, Arg-Gly-Asp peptides are promising... 
block copolymer | polymeric micelle | cancer therapy | cRGD | drug delivery | integrin | THERAPEUTICS | GENE DELIVERY | ANGIOGENESIS | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | OPPORTUNITIES | CHEMISTRY, MULTIDISCIPLINARY | CANCER-THERAPY | CHEMOTHERAPY | CILENGITIDE | MALIGNANT GLIOMA | IN-VITRO | INTEGRINS | Humans | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Brain Neoplasms - drug therapy | Integrins - metabolism | Peptides, Cyclic - chemistry | Organoplatinum Compounds - administration & dosage | Animals | Flow Cytometry | Organoplatinum Compounds - pharmacokinetics | Micelles | Cell Line, Tumor | Polymers - chemistry | Antineoplastic Agents - pharmacokinetics | Mice | Mice, Inbred BALB C | Glioblastoma - drug therapy | Organoplatinum Compounds - therapeutic use | Blood-Brain Barrier | Index Medicus | Human | Drugs | Drug delivery systems | Peptides | Platinum | Ligands | Nanostructure | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Advances in platinum chemotherapeutics
by Harper, Benjamin W and Krause-Heuer, Anwen M and Grant, Maxine P and Manohar, Madhura and Garbutcheon-Singh, K. Benjamin and Aldrich-Wright, Janice R
Chemistry - A European Journal, ISSN 0947-6539, 06/2010, Volume 16, Issue 24, pp. 7064 - 7077
The approved platinum(II)-based anticancer agents cisplatin, carboplatin and oxaliplatin are widely utilised in the clinic, although with numerous... 
Drug delivery | Prodrugs | Targeting | Platinum | CANCER-CELLS | TARGETED DRUG-DELIVERY | FOLATE RECEPTOR | ESTRADIOL DERIVATIVES | LIPOSOMAL CISPLATIN | drug delivery | prodrugs | WALLED CARBON NANOTUBES | CHEMISTRY, MULTIDISCIPLINARY | ESTROGEN-RECEPTOR | MACROMOLECULAR THERAPEUTICS | platinum | targeting | TUMOR-BEARING MICE | IN-VIVO | Carboplatin - chemistry | Humans | Antineoplastic Agents - therapeutic use | Prodrugs - chemistry | Antineoplastic Agents - chemistry | Organoplatinum Compounds - pharmacology | Drug Delivery Systems | Neoplasms - drug therapy | Serum Albumin - therapeutic use | Cisplatin - chemistry | Carboplatin - therapeutic use | Cisplatin - therapeutic use | Nanotubes, Carbon - chemistry | Dendrimers - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Prodrugs - therapeutic use | Serum Albumin - chemistry | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - chemistry | Drugs | Drug delivery systems | Nanotubes | Attachment | Liposomes | Polymers | Anticancer properties | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study
by Van Cutsem, Eric and Boni, C and Tabernero, J and Massuti, B and Middleton, G and Dane, F and Reichardt, P and Pimentel, F.L and Cohn, A and Follana, P and Clemens, M and Zaniboni, A and Moiseyenko, V and Harrison, M and Richards, D.A and Prenen, H and Pernot, S and Ecstein-Fraisse, E and Hitier, S and Rougier, P
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 149 - 156
Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II... 
Platinum compounds | Taxoids | Antineoplastic agents | Combined | Stomach neoplasms | antineoplastic agents | GASTROESOPHAGEAL JUNCTION | ADENOCARCINOMA | DOXORUBICIN | MITOMYCIN | stomach neoplasms | COMBINATION | CHEMOTHERAPY | TRIAL | taxoids | EPIRUBICIN | CISPLATIN | ONCOLOGY | platinum compounds | combined | 1ST-LINE THERAPY | Prospective Studies | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - mortality | Fluorouracil - therapeutic use | Taxoids - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Deoxycytidine - adverse effects | Female | Taxoids - adverse effects | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organoplatinum Compounds - therapeutic use | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
by Yu, Yanan and Yu, TaChung and Guo, Fangfang and Sun, Danfeng and Sun, Tiantian and Ma, Dan and Han, Jixuan and Qian, Yun and Kryczek, Ilona and Nagarsheth, Nisha and Chen, Haoyan and Chen, Yingxuan and Hong, Jie and Zou, Weiping and Fang, Jing-Yuan
Cell, ISSN 0092-8674, 07/2017, Volume 170, Issue 3, pp. 548 - 563.e16
Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure is the major cause of recurrence and poor prognosis in colorectal... 
recurrence | chemoresistance | autophagy | F.nucleatum | Colorectal cancer | miRNA | Toll-like receptor | CELLS | CETUXIMAB | COMMENSAL | STATISTICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | RESISTANCE | SENSITIVITY | OXALIPLATIN | MECHANISMS | MICROBIOTA | EXPRESSION | CELL BIOLOGY | Neoplasm Transplantation | Recurrence | Gastrointestinal Microbiome | Tumor Microenvironment | Drug Resistance, Neoplasm | MicroRNAs - metabolism | Antineoplastic Agents - therapeutic use | Capecitabine - therapeutic use | Autophagy | Platinum Compounds - therapeutic use | Animals | Heterografts | Colorectal Neoplasms - drug therapy | Mice | Toll-Like Receptors - metabolism | Colorectal Neoplasms - pathology | Colorectal Neoplasms - metabolism | Fusobacterium nucleatum - physiology | Yuan (China) | Medical research | Medical colleges | Chemotherapy | MicroRNA | Microbiota (Symbiotic organisms) | Gastrointestinal diseases | Medicine, Experimental | Gram-negative bacteria | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study
by Bauml, Joshua and Seiwert, Tanguy Y and Pfister, David G and Worden, Francis and Liu, Stephen V and Gilbert, Jill and Saba, Nabil F and Weiss, Jared and Wirth, Lori and Sukari, Ammar and Kang, Hyunseok and Gibson, Michael K and Massarelli, Erminia and Powell, Steven and Meister, Amy and Shu, Xinxin and Cheng, Jonathan D and Haddad, Robert
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 14, pp. 1542 - 1549
Purpose There are no approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetuximab. In the... 
ONCOLOGY | RECURRENT | SAFETY | IMMUNOTHERAPY | SQUAMOUS-CELL CARCINOMA | OPEN-LABEL | ANTI-PD-1 | AFATINIB | NIVOLUMAB | Head and Neck Neoplasms - virology | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Platinum Compounds - therapeutic use | Head and Neck Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antibodies, Monoclonal, Humanized - adverse effects | Papillomavirus Infections - complications | Antibodies, Monoclonal, Humanized - therapeutic use | Head and Neck Neoplasms - drug therapy | Carcinoma, Squamous Cell - chemistry | Survival Rate | Disease Progression | Head and Neck Neoplasms - pathology | Disease-Free Survival | Retreatment | Carcinoma, Squamous Cell - drug therapy | Carcinoma, Squamous Cell - secondary | Aged | B7-H1 Antigen - analysis | Index Medicus | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The problem with platinum
by Holmes, David
Nature, ISSN 0028-0836, 11/2015, Volume 527, Issue 7579, pp. S218 - S219
MULTIDISCIPLINARY SCIENCES | DNA Damage - drug effects | DNA Repair - drug effects | Bevacizumab - therapeutic use | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Paclitaxel - therapeutic use | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Carboplatin - therapeutic use | Tamoxifen - therapeutic use | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - blood supply | Neoplasm Staging | Ovarian Neoplasms - drug therapy | Platinum Compounds - pharmacology | Drug Resistance, Neoplasm - drug effects | Ovarian Neoplasms - immunology | Complications and side effects | Chemotherapy | Drug therapy | Ovarian cancer | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text High Sensitivity of BRCA1-Deficient Mammary Tumors to the PARP Inhibitor AZD2281 Alone and in Combination with Platinum Drugs
by Sven Rottenberg and Janneke E. Jaspers and Ariena Kersbergen and Eline van der Burg and Anders O. H. Nygren and Serge A. L. Zander and Patrick W. B. Derksen and Michiel de Bruin and John Zevenhoven and Alan Lau and Robert Boulter and Aaron Cranston and Mark J. O'Connor and Niall M. B. Martin and Piet Borst and Jos Jonkers
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2008, Volume 105, Issue 44, pp. 17079 - 17084
Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailored therapy exists for... 
Tumor burden | Relapse | Platinum | Medical treatment | Antineoplastics | Antibodies | Breast cancer | Genetic mutation | Tumors | Cancer | P-glycoprotein | Drug resistance | DNA repair | GEMM | POLY(ADP-RIBOSE) POLYMERASE | MULTIDISCIPLINARY SCIENCES | breast cancer | CONDITIONAL MOUSE MODEL | BRCA1 MUTATIONS | BREAST-CANCER | GENOMIC STABILITY | THERAPY | GENE | drug resistance | DNA-REPAIR | MULTIDRUG-RESISTANCE | Neoplasm Transplantation | DNA Repair - drug effects | Mice, Transgenic | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors | Platinum Compounds - therapeutic use | BRCA1 Protein - genetics | Drug Resistance, Neoplasm - genetics | Mammary Neoplasms, Animal - pathology | Phthalazines - therapeutic use | Animals | Poly(ADP-ribose) Polymerases - genetics | Cisplatin - therapeutic use | Female | Mammary Neoplasms, Animal - drug therapy | Mice | DNA Damage | Aromatase Inhibitors - therapeutic use | Mammary Neoplasms, Animal - genetics | Genetic aspects | Glycoproteins | Research | Drug therapy | Properties | Health aspects | Proteins | Rodents | Hormone replacement therapy | Hormones | Deoxyribonucleic acid--DNA | Index Medicus | Biological Sciences
Journal Article